Primary Site >> Colorectal Cancer
Gene >> ARL4C
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Ref: [Adoptive immunotherapy of malignant disease using LAK cells]. PMID: 3260466 |
Ref: [Potent effects of the prostaglandin synthesis inhibitor indomethacin on the cellular immune response in gastrointestinal cancer patients]. PMID: 2778378 |
Ref: The clinical significance of interleukin-2. PMID: 2092277 Ref: Lymphokine-activated killer cell cytotoxicity against human colon carcinomas enhanced by monoclonal antibody D612. PMID: 2123477 Ref: Granulocyte-monocyte colony-stimulating-factor augments the interleukin-2-induced cytotoxic activity of human lymphocytes in the absence and presence of mouse or chimeric monoclonal antibodies (mAb 17-1A). PMID: 2199042 Ref: [Immunotherapy and quality of life]. PMID: 2344201 |
Ref: Adjuvant adoptive immunotherapy with IL2 and lymphocytes from tumor-bearing mice: in vitro tumor-stimulated lymphocytes are more effective than LAK cells. PMID: 1787836 Ref: Immunological effects of levamisole in vitro. PMID: 1790137 Ref: [Splenic or hepatic arterial injections of interleukin-2 with chemotherapeutic agents for hepatic metastases]. PMID: 1944193 |
Ref: [Significance of antitumor effects and immunological response on endogenously induced LAK therapy for primary or metastatic liver tumor]. PMID: 1530292 Ref: Clinical trials of intrasplenic arterial infusion of interleukin-2 (IS-IL-2) to patients with advanced cancer. PMID: 1622739 |
Ref: Study of effect of surgical stress on immunity in patients with gastrointestinal cancer. PMID: 8274052 Ref: Analysis of the relationship between stage of differentiation and NK/LAK susceptibility of colon carcinoma cells. PMID: 8428794 |
Ref: [Observation of the effects of LAK/IL-2 therapy combining with Lycium barbarum polysaccharides in the treatment of 75 cancer patients]. PMID: 7720497 Ref: The clinical experience with interleukin-2 in cancer therapy. PMID: 7820182 |
Ref: Effect of essential fatty acids on natural cytotoxicity in patients with colorectal cancer. PMID: 7781792 |
Ref: [Vaccination with genetically modified IL-2 secreting cells in a rat model of colonic carcinoma]. PMID: 8695924 |
Ref: Interleukin-7 (IL-7) in colorectal cancer: IL-7 is produced by tissues from colorectal cancer and promotes preferential expansion of tumour infiltrating lymphocytes. PMID: 9042431 Ref: Extracellular adenosine 5' triphosphate involvement in the death of LAK-engaged human tumor cells via P2X-receptor activation. PMID: 9143936 Ref: Interleukin-2-activated killer cell activity in colorectal tumor patients: evaluation of in vitro effects by prothymosin alpha1. PMID: 9292704 Ref: IL-2-Activated Killer Cells and Native Cytokines in Treatment of Patients with Advanced Cancer. PMID: 12687071 |
Ref: Docetaxel treatment of HT-29 colon carcinoma cells reinforces the adhesion and immunocytotoxicity of peripheral blood lymphocytes in vitro. PMID: 9499461 |
Ref: Morphological appearance, content of extracellular matrix and vascular density of lung metastases predicts permissiveness to infiltration by adoptively transferred natural killer and T cells. PMID: 16047144 |
Ref: [Study on radiation sensitivity of colorectal cancer cells using gene expression profile]. PMID: 19598022 |
Ref: Decrease of the regulatory T-cell population by adoptive T-cell transfer in a mouse colorectal cancer transplant model. PMID: 22812187 |
Ref: Arl4c expression in colorectal and lung cancers promotes tumorigenesis and may represent a novel therapeutic target. PMID: 25486429 |
Ref: Clinical and prognostic significance of Arl4c expression in colorectal cancer. PMID: 26756615 |